Abstract 180P
Background
Immune checkpoint inhibitors (ICI) have shown limited efficacy in high-grade serous carcinomas (HGSC). The NeoPembrOv randomized phase II trial investigated the combination of Pembrolizumab (P) with NeoAdjuvant ChemoTherapy (NACT), providing an opportunity to identify resistance mechanisms.
Methods
Patients (n=91) were randomized 2:1 to NACT+P or NACT. Paired samples were analyzed using RNA-seq (n=53) and multiplexed immunofluorescence staining (n=64) for CD8, PD-1, ActCasp3, panCK, CD31, and VEGFR2. Immune and endothelial signatures were assessed using MCP-counter and quanTIseq algorithms. Cell densities and nearest neighbors were determined based on InForm software output. We investigated the impact of NACT±P on the tumor microenvironment and identified parameters associated with survival. As no transcriptomic dataset of HGSC patients under ICI was available, we used an external validation cohort of 102 head and neck cancer patients.
Results
Analysis of DEG revealed a significant enrichment of T cell activation/differentiation pathways in the NACT+P arm only after treatment. We showed a significant increase in CD8+PD-1+ T cells density in tumor islets in the NACT+P arm compared to NACT (p=0.015). This increase observed in 15% of cases (n=6/41) was associated with improved overall survival (OS) (LR test, p=0.01).The median distance between apoptotic tumor and the nearest CD8+PD-1+ cell significantly decreased after NACT+P. Univariate cox models revealed a negative association between the MCP-counter endothelial cell signature and survival (HR=1.97, 95% CI [1.10-3.49], p=0.02) in the NACT+P arm, with a significant interaction with treatment arm (p=0.046). In situ analysis confirmed the negative predictive impact of high expression of VEGFR2 on CD31+ endothelial cells in patients receiving NACT+P, significantly affecting OS (p=0.005). KDR expression (VEGFR2) was validated as a predictive biomarker in an external cohort for OS (p=0.044).
Conclusions
Only a subset of HGSC patients can benefit from ICI. Targeting VEGFR2+ endothelial cells may overcome resistance. Clinical trials using VEGFR2 inhibitors are warranted.
Clinical trial identification
NCT03275506.
Legal entity responsible for the study
Arcagy-Gineco.
Funding
ARC Foundation.
Disclosure
O. Le Saux: Financial Interests, Personal, Advisory Board: Novartis, MSD, GSK; Financial Interests, Personal, Invited Speaker: Lilly, AstraZeneca, Clovis; Financial Interests, Institutional, Trial Chair: Novartis, Hospira-Pfizer foundation, Astellas. E. Coquan: Financial Interests, Personal, Advisory Board: Sanofi, MSD, BMS, Ipsen, AstraZeneca. I.L. Ray-Coquard: Financial Interests, Personal, Advisory Board: Roche, GSK, AstraZeneca, Mersana, Deciphera, Amgen, Oxnea, Merck Sereno, Agenus, Novartis, Macrogenics, Clovis, EQRX, Adaptimmune, Eisai, SUTRO, BMS, Adaptimmune, Daiichi Sankyo; Financial Interests, Institutional, Other, COLIBRI translational research: BMS; Financial Interests, Institutional, Advisory Board, translational research NEOPREMBROV trial: MSD; Non-Financial Interests, Personal, Principal Investigator: PAOLA1; Non-Financial Interests, Personal, Other, President: Gineco. All other authors have declared no conflicts of interest.
Resources from the same session
26P - Liquid biopsy as promising source of plasma extracellular vesicle biomarkers of response to Cabozantinib (CABO) plus Durvalumab (DURVA) in advanced urothelial carcinoma (UC) or non-UC variant histologies (VH) patients (the Phase 2 ARCADIA trial)
Presenter: Veronica Huber
Session: Poster Display
27P - Peripheral biomarker analysis in patients with advanced urothelial carcinoma (UC) after platinum chemotherapy treated with Cabozantinib (CABO) plus Durvalumab (DURVA): preliminary analysis from the Phase 2 ARCADIA trial.
Presenter: Francesco Sgambelluri
Session: Poster Display
28P - 3-year follow-up analysis of disease-free survival in CheckMate 274 by PD-L1 expression using tumor cell and combined positive scoring algorithms
Presenter: Frank Stenner-Liewen
Session: Poster Display
30P - CD4+ T cells within the tumor microenvironment are an independent predictor of recurrence, but do not improve the performance of a predictive model in oral squamous cell carcinoma
Presenter: Sangeeta Bisheshar
Session: Poster Display
31P - Characterization of pre-exhausted / exhausted state of CD8+ T cells in HRAS mutant head and neck carcinomas (HNSCCs). Implications for response to immune checkpoint blockade (ICB).
Presenter: Ioannis Kotsantis
Session: Poster Display
32P - Tumor-agnostic plasma assay for circulating tumor DNA predicts outcome in recurrent and/or metastatic squamous cell carcinoma of the head and neck treated with a PD-1 inhibitor
Presenter: Natasha Honoré
Session: Poster Display
34P - Heterogeneous response to Immune Checkpoint Inhibitors in metastatic melanoma patients - assessment of lesion-level response with 18F-FDG PET/CT
Presenter: Katja Strasek
Session: Poster Display